Formulas for estimating the costs averted by sexually transmitted infection (STI) prevention programs in the United States

Table 4 Formulas for estimating averted direct medical costs of chlamydia, gonorrhea, syphilis, and congenital syphilis

Sequelae costs averted by treatment of people with chlamydia, gonorrhea, and syphilis
Chlamydia	[(C_w)(0.16)(0.925)(0.70)($1,995)] + [(C_m+C_msm)(0.03)(0.925)(0.70)($274)]
Gonorrhea	[(G_w)(0.14)(0.79)(0.70)($1,995)] + [(G_m+G_msm)(0.03)(0.90)(0.70)($274)]
Syphilis	(S_w+S_m+S_msm)($572)
Congenital syphilis treatment costs averted by treatment of syphilis in women
	[X₁₃ + 0.7(X₁₄) + 0.3(X₁₅)] [(0.5)($6,738)]
Treatment and sequelae costs averted by reducing transmission of chlamydia, gonorrhea, and syphilis in the population
Chlamydia	[(Ĉ_w+ Ĉ_m)(0.5)($171)] + [(Ĉ_msm)(0.5)($26)]
Gonorrhea	[(Ĝ_w+ Ĝ_m)(0.5)($206)] + [(Ĝ_msm)(0.5)($68)]
Syphilis	(Ŝ_w+Ŝ_m+Ŝ_msm)(0.5)($572)

The C_i, G_i, S_i, Ĉ_i, Ĝ_i, and Ŝ_i terms are defined in Table 3. The X_i, Y_i, and Z_i terms are defined in Table 2. Syphilis cases include primary and secondary (P&S) syphilis only.

ISSN: 1478-7547